Contract Service Directory


Unither Pharmaceuticals





Company Headquarters

755 Jefferson Road
Rochester, NY 14623
United States

Contract Service Directory

    Related Content


    • Breaking News | Clinical Trial Materials | Clinical Trials | Formulation Development | Industry News
      Recipharm, Aptahem Enter Formulation Development Pact

      Recipharm, Aptahem Enter Formulation Development Pact

      Recipharm will develop an injectable formulation of Apta-1 drug candidate for Phase I study
      12.17.19

    • Biologics, Proteins, Vaccines | CRO News | Drug Discovery | Preclinical Outsourcing
      Charles River to Acquire HemaCare Corp. for $380M

      Charles River to Acquire HemaCare Corp. for $380M

      Expands scientific capabilities for cell and gene therapies
      12.16.19


    • Breaking News | Promotions & Moves
      Agios Pharmaceuticals Appoints CSO

      Agios Pharmaceuticals Appoints CSO

      Dr. Car spent 25 years at Bristol-Myers Squibb and its legacy companies
      12.02.19

    • Breaking News | cGMP Manufacture | Industry News
      WuXi STA, Impact Therapeutics Enter Strategic Pact

      WuXi STA, Impact Therapeutics Enter Strategic Pact

      WuXi STA will serve as Impact’s preferred contract development and manufacturing partner for its pipeline.
      11.21.19

    • AAPS Exhibitor List

      ...
      10.29.19


    • Breaking News | Collaborations & Alliances | Industry News
      Mayne, Mithra Sign 20-Year License and Supply Agreement in the US

      Mayne, Mithra Sign 20-Year License and Supply Agreement in the US

      For Mayne’s novel oral contraceptive E4/DRSP; launch is expected in 1H of 2021
      10.02.19

    • Breaking News | cGMP Manufacture | Fill/Finish | Industry News
      Minerva, Catalent Enter Long-Term Commercial Supply Pact

      Minerva, Catalent Enter Long-Term Commercial Supply Pact

      Catalent will manufacture and package the finished dose form of Roluperidone at its facility in Schorndorf, Germany
      09.24.19

    • Breaking News | Collaborations & Alliances | Industry News | Scale-up/Technology Transfer
      Catalent, Acura Enter Clinical Manufacturing Pact

      Catalent, Acura Enter Clinical Manufacturing Pact

      Catalent to scale-up manufacturing of LTX-03 for clinical testing
      09.16.19


    • Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery
      Secarna Enters Oncology Research Alliance with Global Pharma Co.

      Secarna Enters Oncology Research Alliance with Global Pharma Co.

      Will leverage LNAplus platform to support research and discovery in the field of oncology
      09.11.19

    • Biologics, Proteins, Vaccines | Drug Delivery | Injectables
      Growth in Biologics and Maintaining Patient Satisfaction

      Growth in Biologics and Maintaining Patient Satisfaction

      Vicki A. Barbur of Battelle discusses the driving forces for biologics, the challenges, and new delivery methods
      Kristin Brooks, Contrct Pharma 08.09.19

    • Drug Development | Industry News
      Zambon Acquires Sofinnova Partners’ Breath Therapeutics

      Zambon Acquires Sofinnova Partners’ Breath Therapeutics

      Italian pharma company purchases Breath Therapeutics for €500 million, with €140 million up front
      07.25.19


    • Trials & Filings
      La Jolla Pharma Receives Orphan Designation for Malaria Treatment

      La Jolla Pharma Receives Orphan Designation for Malaria Treatment

      LJPC-0118, artesunate, demonstrated to be superior to quinine in reducing mortality in patients with falciparum malaria infection
      07.23.19

    • cGMP Manufacture | Industry News
      Lubrizol Acquires Bavaria Medizin Technologie GmbH

      Lubrizol Acquires Bavaria Medizin Technologie GmbH

      Expands Lubrizol’s medical device design, development and manufacturing capabilities
      07.16.19

    • Drug Development | Industry News
      Rafael Pharma Signs License Agreement with Ono Pharmaceutical

      Rafael Pharma Signs License Agreement with Ono Pharmaceutical

      Aims to accelerate development and commercialization of cancer drug candidate CPI-613 (devimistat) in Japan and other Asian countries
      06.25.19